Antibiotics

Novo Holdings, Gurnet Point Close Acquisition of Paratek Pharmaceuticals

Novo Holdings, controlling shareholder in drugmaker Novo Nordisk, and healthcare investment firm Gurnet Point closed their acquisition of US antibiotics specialist Paratek Pharmaceuticals in a transaction valued at $462 million. Novo Holdings said that this is its largest individual investment in antimicrobial resistance (AMR) therapies to date.

Sandoz Invests in Extra European Antibiotic Capacity

Sandoz, the generics arm of Swiss drugmaker Novartis, has announced plans to spend an additional €50 million on raising European manufacturing capacity for finished dosage forms of amoxicillin and other key penicillin products.

Roche and Warp Drive Bio Link on Antibiotics

Pfizer Strikes Again With Astra Antibiotics Deal

Evonik to Acquire Norel’s Probiotics Lines

MEPs urge EU not to Reauthorize Glyphosate

Drug Firms Urge Governments to Fight Superbugs

Sanofi Seals two Oncology Partnerships

Institution of Chemical Engineers Names Most Important Chemically Engineered Inventions

Pfizer Takes its Shot at a Vaccine for Evasive Superbug

U.S. Government Taps GlaxoSmithKline for New Antibiotic

Optimer Shares Rise After Report Names Glaxo, Cubist as Potential Buyers

Antibiotics Crisis Prompts Rethink on Risks, Rewards

EU Doctors Turn to Last-Ditch Antibiotics as Resistance Grows

Impact of New Regulations on Global Antibiotics Production